Skip to main content
Equibles
ZBIO logo

ZBIO · Zenas BioPharma, Inc.

Track ZBIO — free

Use ZBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$31.12 +0.02 (+0.06%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$2.03B
Shares
65.18M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$31.12 Open$31.48 Day$31.12–32.32 52W close$15.20–43.17 Avg vol 30d645K Short int11.7M · 18.0% float · 14.2d Short vol77% Last earningsJan 5, 2026 DataSep 2024–Sep 2026 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.00M
Trailing 12 months
Net income (TTM)
−$484.38M
Trailing 12 months
Revenue growth YoY
+100.0%
Year over year
Operating margin
-3,830.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-11.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+50.8%
Year over year · more shares
Price change (1Y)
+57.2%
Trailing year
Short interest
18.0%
Latest settlement · 14.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +20%
above
Price vs 50-day avg +0%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 57%
mid-range
Momentum
relative strength
Strong
1-month return +7%
trailing
6-month return +40%
trailing
YTD return −14%
this year
Relative strength +22%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $31 › 200d $26 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.95% of float · ▲ +0.4% MoM · 14.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
146 holders — near 2-yr high, broad support
Squeeze score 83
high risk · 0–100
Fundamentals
Strong
Revenue growth +100%
Y/Y
EPS growth +29%
Y/Y
Free cash flow $-172.4M
Quant / Vol
risk profile
Very High
Volatility 107%
annualized · 1-yr
Max drawdown −65%
past year
ATR 5.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+20% Bullish
Price vs 50-day avg
+0% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
57% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $31 › 200d $26 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +28 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
17.95% of float · ▲ +0.4% MoM · 14.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
146 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $15 Now $31 · 57% Range high $43
vs 200-day avg +20% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ZBIO
Zenas BioPharma, Inc.
this stock
$2.03B -14.3% +100.0% — 18.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
146
% held
94.5%
Net QoQ
+3.5M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
164
View
Short & Settlement
Short Interest Rising
Shares short
11.7M
Days to cover
14.2d
Change
+43.3K sh
View
Short Volume
Short vol %
77%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
292
Value
$9.1K
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
46.3%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$10.0M
Net income (FY)
$-377.7M
EPS diluted
$-8.44
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
10
View
Exempt Offerings
Offering
$200.1M
Filed
May 14, 2024
View
Earnings & Events
Earnings Calls
Last call
Jan 5, 2026
View

Performance

5D 20D 120D MTD YTD
ZBIO -5.5% +6.6% +39.6% -3.7% -14.3%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -4.3% +8.3% +21.7% -3.4% -26.4%
Key facts CIK 1953926 CUSIP 98937L105 13F (30d) 63 filings 61 filers Visit website Investor relations